AUG 13, 2026 · OBSERVATIONAL STUDY
A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia
ClinicalTrials.gov
This is a completed prospective observational registry study with no results posted; it describes treatment patterns and outcomes in routine practice but carries no efficacy or safety data in this record.
Reported
Planned enrollment2390
Primary outcome measureTime to treatment failure (TTF), up to 24 m…
Study duration (follow-up)Up to 24 months